IBIO - iBio, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.80
-0.01 (-1.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.81
Open0.80
Bid0.61 x 2200
Ask0.83 x 3000
Day's Range0.80 - 0.85
52 Week Range0.60 - 3.60
Volume57,272
Avg. Volume156,456
Market Cap14.669M
Beta (3Y Monthly)-1.33
PE Ratio (TTM)N/A
EPS (TTM)-1.54
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    iBio and CC-Pharming Hold First Design and Strategy Meeting

    NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced the beginning of a four-day design and strategic planning meeting with executives and technical experts from CC-Pharming Ltd of Beijing China at iBio’s development and manufacturing facility in Bryan Texas. The meeting initiates the first stage of the companies’ business collaboration and will include work on product, process, and facility design for a monoclonal therapeutic antibody product: a plant-derived, bio-better rituximab. The companies will hold a joint press briefing at 5 p.m. on Tuesday, October 2, at the Stella Hotel, adjacent to the iBio site.

  • GlobeNewswire2 months ago

    iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance

    IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that NYSE Regulation has accepted the Company’s plan to regain compliance with the Exchange’s continued listing standards set forth in Section 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) and has granted a plan period through December 6, 2019, subject to periodic review by the Exchange, including quarterly monitoring, for compliance with the initiatives outlined in the plan. If the Company is not in compliance with the continued listing standards by December 6, 2019, or if the Company does not make progress consistent with the plan during the plan period, the NYSE Regulation staff will initiate delisting proceedings as appropriate.

  • ACCESSWIRE4 months ago

    Free Technical Research on Nektar Therapeutics and Three More Biotech Equities

    On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN).

  • Why iBio Inc’s (NYSEMKT:IBIO) Ownership Structure Is Important
    Simply Wall St.5 months ago

    Why iBio Inc’s (NYSEMKT:IBIO) Ownership Structure Is Important

    I am going to take a deep dive into iBio Inc’s (AMEX:IBIO) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure of a companyRead More...

  • ACCESSWIRE5 months ago

    Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).

  • Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?
    Simply Wall St.6 months ago

    Should iBio Inc’s (NYSEMKT:IBIO) Recent Earnings Decline Worry You?

    After reading iBio Inc’s (AMEX:IBIO) latest earnings update (31 December 2017), I found it beneficial to look back at how the company has performed in the past and compare thisRead More...

  • iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer?
    Simply Wall St.10 months ago

    iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer?

    When iBio Inc (AMEX:IBIO) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industryRead More...

  • Capital Cube11 months ago

    ETFs with exposure to iBio, Inc. : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube11 months ago

    ETFs with exposure to iBio, Inc. : November 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iBio, Inc. Here are 5 ETFs with the largest exposure to IBIO-US. Comparing the performance and risk of iBio, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017
    Capital Cube11 months ago

    iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017

    Categories: Yahoo FinanceGet free summary analysis iBio, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of iBio, Inc. – Genocea Biosciences, Inc., Johnson & Johnson, Aviragen Therapeutics Inc, Newlink Genetics Corporation, Altimmune, Inc., Nektar Therapeutics, Achaogen, Inc., Emergent BioSolutions Inc. and Immunomedics, Inc. (GNCA-US, JNJ-US, ... Read more (Read more...)

  • Zacks Small Cap Research11 months ago

    AEMD: Upcoming FDA Meeting Expected to Define U.S. Regulatory Pathway

    Cash used in operating activities was $1.0M in Q2 and $2.1M in 1H 2018.  Relative to the balance sheet, AEMD exited Q2 with $920k in cash but subsequent to quarter-end, they raised $6.0M ($5.3M net) via a secondary equity offering (5.4M shares @ $1.10/share, with 100% warrant coverage: 5yrs, $1.10 strike).  AEMD expects current cash (i.e.